Rome, November 21 (Adnkronos Health) – “In recent years we have had innovative therapies for myasthenia gravis. For now, they are limited to certain types of patients and there are rather limited access criteria. They are well tolerated, safe therapies, and most importantly, they have been proven to be effective even in patients who did not respond to previous therapies.” These were the words spoken by the director of Neuroimmunology and Neuromuscular Diseases, Fondazione Irccs Carlo Besta Neurological Institute of Milan, at an event organized in Rome by Omar – Rare Diseases Observatory with a non-conditioning contribution from Ucb Pharma entitled ‘Protection of patients with rare diseases: myasthenia gravis as a paradigm’.
“There are two unmet needs of myasthenia gravis patients – continues Maggi – The fact that traditional therapies work little or only partially, causing constant disorders in people affected by this pathology, and that side effects are always associated with traditional therapies. There is still much to be done, but I am convinced that these new therapies have opened the way to truly satisfactory control of the disease”.
